NRIX · Nurix Therapeutics, Inc. · Documents
$26.10
+1.17 (+4.69%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$2.72B
Shares
109.25M
Volume · Oct 20
3.97M
Avg daily vol (3M)
1.56M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 10-Q | Nurix Therapeutics posted $373.1 million net income for the nine months ended August 31, 2026, including $653.2 million of Roche license revenue. It held $1.1 billion in cash, cash equivalents and marketable securities and discontinued zelebrudomide in August 2026. | 2026-10-13 | 2026-08-31 | |
| 8-K | Nurix Therapeutics reported revenue of $673.1 million and net income of $549.8 million for the three months ended August 31, 2026, driven primarily by $653.2 million of Roche license revenue, and $1.1 billion in cash, cash equivalents and marketable securities. | 2026-10-13 | 2026-10-12 | |
| Investor Event Transcript | — | 2026-09-16 | 2026-08-31 | |
| Investor Event Transcript | — | 2026-09-08 | 2026-08-31 | |
| 10-Q | — | 2026-07-09 | 2026-05-31 | |
| 8-K | — | 2026-07-09 | — | |
| 8-K | — | 2026-06-11 | — | |
| 8-K | — | 2026-06-08 | 2026-06-06 | |
| Investor Event Transcript | — | 2026-06-03 | 2026-05-31 | |
| Investor Event Transcript | — | 2026-05-20 | 2026-05-31 | |
| 8-K | — | 2026-05-15 | — | |
| Investor Event Transcript | — | 2026-04-13 | 2026-05-31 | |
| 8-K | — | 2026-04-08 | — | |
| 10-Q | — | 2026-04-08 | 2026-02-28 | |
| DEF 14A | — | 2026-03-27 | 2026-05-15 | |
| 8-K | — | 2026-03-06 | — | |
| 10-K | — | 2026-01-28 | 2025-11-30 | |
| 8-K | — | 2026-01-28 | — | |
| 8-K | — | 2026-01-12 | — | |
| 8-K | — | 2025-12-09 | 2025-12-06 | |
| 8-K | — | 2025-11-10 | 2025-11-06 | |
| 8-K | — | 2025-10-22 | — | |
| 8-K | — | 2025-10-22 | — | |
| 8-K | — | 2025-10-09 | — | |
| 10-Q | — | 2025-10-09 | 2025-08-31 | |
| 8-K | — | 2025-09-03 | — | |
| 8-K | — | 2025-08-22 | 2025-08-19 | |
| 8-K | — | 2025-07-09 | — | |
| 10-Q | — | 2025-07-09 | 2025-05-31 | |
| 8-K | — | 2025-06-12 | — | |
| 8-K | — | 2025-05-19 | — | |
| 10-Q | — | 2025-04-08 | 2025-02-28 | |
| 8-K | — | 2025-04-08 | — | |
| DEF 14A | — | 2025-03-28 | 2025-05-19 | |
| 8-K | — | 2025-03-13 | 2025-03-11 | |
| 10-K | — | 2025-01-28 | 2024-11-30 | |
| 8-K | — | 2025-01-28 | — | |
| 8-K | — | 2025-01-13 | — | |
| 8-K | — | 2024-12-10 | 2024-12-09 | |
| 8-K | — | 2024-10-31 | — | |
| 8-K | — | 2024-10-16 | 2024-10-15 | |
| 8-K | — | 2024-10-11 | — | |
| 10-Q | — | 2024-10-11 | 2024-08-31 | |
| 8-K | — | 2024-09-05 | — | |
| 10-Q | — | 2024-07-11 | 2024-05-31 | |
| 8-K | — | 2024-07-11 | — | |
| 8-K | — | 2024-06-17 | 2024-06-16 | |
| 8-K | — | 2024-05-21 | 2024-05-20 | |
| 8-K | — | 2024-04-12 | 2024-04-11 | |
| 10-Q | — | 2024-04-10 | 2024-02-29 |
Showing 1–50 of 115 filings
Key facts
CIK
1549595
CUSIP
67080M103
13F (30d)
11 filings
11 filers
Visit website
Investor relations